CYP3A4*18基因型对唑吡坦在健康回族志愿者体内的药代动力学的影响

doi:10.5246/jcps.2016.02.013

中国药学(英文版) ›› 2016, Vol. 25 ›› Issue (2): 122-127.DOI: 10.5246/jcps.2016.02.013

CYP3A4*18基因型对唑吡坦在健康回族志愿者体内的药代动力学的影响

吴秀君¹, 郭涛², 张凤芹¹, 马然¹, 左金梁^3*

1. 辽宁中医药大学附属医院, 辽宁沈阳 110032
2. 沈阳军区总医院药剂科, 辽宁沈阳 110015
3. 天津医科大学药学院, 天津 300070

收稿日期:2015-07-25 修回日期:2015-10-23 出版日期:2016-02-29 发布日期:2015-11-23
通讯作者: Tel.: 022-83336673, E-mail: zuo615@163.com
基金资助:
Funds of the Chinese Army Medical Science and Technology Research “Eleventh Five-Year Plan” Project (Grant No. 06G023).

Effect of CYP3A4*18 genotype on the pharmacokinetics of zolpidem in healthy Chinese Hui subjects

Xiujun Wu¹, Tao Guo², Fengqin Zhang¹, Ran Ma¹, Jinliang Zuo^3*

1. Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang 110032, China
2. Department of Pharmacy, the General Hospital of Shenyang Military Region, Shenyang 110015, China
3. College of Pharmacy, Tianjin Medical University, Tianjin 300070, China

Received:2015-07-25 Revised:2015-10-23 Online:2016-02-29 Published:2015-11-23
Contact: Tel.: 022-83336673, E-mail: zuo615@163.com
Supported by:
Funds of the Chinese Army Medical Science and Technology Research “Eleventh Five-Year Plan” Project (Grant No. 06G023).

摘要/Abstract

摘要：

本研究旨在研究CYP3A4*18基因型对唑吡坦在健康回族人体内的药代动力学行为的影响。采用多聚酶链反应-限制性片段(PCR-RELP)分析,检测200名健康回族志愿者的CYP3A4*18等位基因。根据CYP3A4*18等位基因筛选结果,选择CYP3A4*1/*1,CYP3A4*1/*18和CYP3A4*18/*18携带者各6名,单剂量口服给予10 mg酒石酸唑吡坦片,分别于给药前和给药后不同时间点采集血浆样品。使用HPLC-FLD法测定唑吡坦血药浓度,采用DAS2.0软件计算药代动力学参数,并采用SPSS17.0软件进行统计分析。结果显示不同基因型受试者唑吡坦的药代动力学行为有明显差异。杂合突变组(*1/*18)和纯合突变组(*18/*18)的唑吡坦C_max分别为野生组(*1/*1)的0.89 (95% CI: 0.65–1.12)和0.57 (95% CI: 0.47–0.66);AUC_0–t分别为*1/*1组的0.74 (95% CI: 0.22–1.26) 和0.61 (95% CI: 0.24–0.98)。唑吡坦药代动力学参数呈现明显的基因-剂量效应(P<0.05)。本研究证明CYP3A4*18等位基因增强了CYP3A4对唑吡坦的代谢水平,对唑吡坦的人体内药代动力学行为有显著影响。

关键词: 唑吡坦, CYP3A4*18, 药代动力学, 中国回族志愿者

Abstract:

In the present study, we aimed to investigate the effect of CYP3A4*18 genotype on the pharmacokinetics of zolpidem in healthy Chinese Hui volunteers.Blood samples were collected from volunteers for CYP3A4 genotyping using a polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay. A pharmacokinetic study was then carried out in three groups with CYP3A4*1/*1 (n = 6), CYP3A4*1/*18 (n = 6) and CYP3A4*18/*18 (n = 6) genotypes. Plasma levels of zolpidem were determined by HPLC-FLD method before and after a single oral dose of 10 mg zolpidem tartrate tablet. Significant differences were observed in the pharmacokinetic parameters of zolpidem among the three genotype groups (P<0.05). Compared with the CYP3A4*1/*1 group, the C_max of zolpidem in *1/*18 and *18/*18 groups (mean, 95% CI) was 0.89 (0.65–1.12) and 0.57 (0.47–0.66), respectively, and the AUC₀_–_t in the *1/*18 and *18/*18 groups (mean, 95% CI) was 0.74 (0.22–1.26) and 0.61 (0.24–0.98), respectively. There was a significant trend towards lower C_maxand AUC₀_–_t values of zolpidem in individuals with more CYP3A*18 alleles, suggesting a gene-dosage effect.The study demonstrated that the CYP3A4*18 allele played an important role in the pharmacokinetics of the zolpidem after oral administration.

Key words: Zolpidem, CYP3A4*18, Pharmacokinetics, Chinese Hui

中图分类号:

R969.1

Supporting:

吴秀君, 郭涛, 张凤芹, 马然, 左金梁. CYP3A4*18基因型对唑吡坦在健康回族志愿者体内的药代动力学的影响[J]. 中国药学(英文版), 2016, 25(2): 122-127.

Xiujun Wu, Tao Guo, Fengqin Zhang, Ran Ma, Jinliang Zuo. Effect of CYP3A4*18 genotype on the pharmacokinetics of zolpidem in healthy Chinese Hui subjects[J]. Journal of Chinese Pharmaceutical Sciences, 2016, 25(2): 122-127.

参考文献

[1] Langtry, H.D.; Benfield, P. Drugs. 1990, 55, 291-313.

[2] Darcourt, G.; Pringuey, D.; Sallière, D. J. Psychopharmacol. 1999, 13, 81-93.

[3] Criswell, H.E.; Simson, P.E.; Knapp, D.J. J. Pharmacol. Exp. Ther. 1995, 273, 526-536.

[4] Holm, K.J.; Goa, K.L. Drugs. 2000, 59, 865-889.

[5] Lancel, M. Sleep. 1999, 22, 33-42.

[6] Lavoisy, J.; Zivkovic, B.; Benavides, J.; Perrault, G.H.; Robert, P. L'Encéphale. 1992, 18, 379-392.

[7] Dang, A.; Garg, A.; Rataboli, P.V. CNS. Neurosci. Ther. 2011, 17, 387-397.

[8] Garnier, R.; Guerault. E.; Muzard, D.; Azoyan, P. J. Toxicol. Clin. Toxicol. 1994, 32, 391-404.

[9] Gock, S.B.; Wong, S.H.; Nuwayhid, N.; Venuti, S.E.; Kelley, P.D.; Teggatz, J.R.; Jentzen, J.M. J. Anal. Toxicol. 1999, 23, 559-562.

[10] Kuzniar, T.J.; Balagani, R.; Radigan, K.A.; Factor, P.; Mutlu, G.M. Am. J. Ther. 2010, 17, 72-74.

[11] Levine, B.; Wu, S.C.; Smialek, J.E. J. Forensic. Sci. 1999, 44, 369-371.

[12] Meeker, J.E.; Som, C.W.; Macapagal, E.C.; Benson, P.A. J. Anal. Toxicol. 1995, 19, 531-534.

[13] Paradis, C.M.; Siegel, L.A.; Kleinman, S.B. Prim. Care. Companion. CNS. Disord. 2012, 14pii: PCC.12br01363. doi: 10.4088/PCC.12br01363.

[14] Ware, J.C.; Walsh, J.K.; Scharf, M.B.; Roehrs, T.; Roth, T.; Vogel, G.W. Clin. Neuropharmacol. 1997, 20, 116-125., 293, 435-443., 10, 616-620.

[17] Pichard, L.; Gillet, G.; Bonfils, C. Drug. Metab. Dispos. 1995, 23, 1253-1262.

[18] Von Moltke, L.L.; Greenblatt, D.J.; Granda, B.W. Br. J. Clin. Pharmacol. 1999, 48, 89-97.

[19] Meyer, U.A. Proc. Natl. Acad. Sci. USA. 1994, 91, 1983-1984. , 29, 268-273.

[21] Duricová, J.; Grundmann, M. Ceska. Slov. Farm. 2011, 60, 276-282.

[22] Lee, S.J.; Lee, S.S.; Jeong, H.E.; Shon, J.H.; Ryu, J.Y.; Sunwoo, Y.E.; Liu, K.H.; Kang, W.; Park, Y.J.; Shin, C.M.; Shin, J.G. Drug Metab. Dispos. 2007, 35, 2095-2110.

[23] Dai, D.; Tang, J.; Rose, R.; Hodgson, E.; Bienstock, R.J.; Mohrenweiser, H.W.; Goldstein, J.A. J. Pharmacol. Exp. Ther. 2001, 299, 825-831.

[24] Kang, Y.S.; Park, S.Y.; Yim, C.H.; Kwak, H.S.; Gajendrarao, P.; Krishnamoorthy, N.; Yun, S.C.; Lee, K.W.; Han, K.O. Clin. Pharmacol. Ther. 2009, 85, 312-318.

[25] Streetman, D.S.; Bertino, J.S.; Nafziger, A.N. Pharmacogenetics. 2000, 10, 187-216.

[26] Shen, M.; Shi, Y.; Xiang, P. Forensic. Sci. Int. 2013, 227, 77-81.

[27] Yamamoto, T.; Nagafuchi, N.; Ozeki, T.; Kubota, T.; Ishikawa, H.; Ogawa, S.; Yamada, Y.; Hirai, H.; Iga, T. Drug Metab. Pharmacokinet. 2003, 18, 267-268.

[28] Zuo, J.; Xia, D.; Jia, L.; Guo, T. Pharmazie. 2012, 67, 639-644.[29] Xia, D.Y.; Yang, L.; Guo, T. Chin. Pharm. 2010, 21, 504-506.

[20] Hsieh, K.P.; Lin, Y.Y.; Cheng, C.L. Drug. Metab. Dispos. 2001

[15] Greenblatt, D.J.; Harmatz, J.S.; von, Moltke, L.L.; Wright, C.E.; Durol, A.L., Harrel-Joseph, L.M.; Shader, R.I. 2000J. Pharmacol. Exp. Ther.

[16] Staner, L.; Eriksson, M.; Cornette, F.; Santoro, F.; Muscat, N.; Luthinger, R.; Roth, T. Sleep Med. 2009

CYP3A4*18基因型对唑吡坦在健康回族志愿者体内的药代动力学的影响

Effect of CYP3A4*18 genotype on the pharmacokinetics of zolpidem in healthy Chinese Hui subjects

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	杨雁芳, 韦玮, 张雷, 徐嵬, 杨秀伟. UPLC-MS/MS法测定都梁丸中37个成分在大鼠体内的药代动力学[J]. 中国药学(英文版), 2023, 32(7): 560-573.
[2]	李晓娇, 栾树鑫, 张洪, 万洪泉, 陈红, 刘成娇, 刘畅, 丁艳华. 单剂量长效利培酮注射液在中国精神分裂症患者体内的药代动力学、药效学和安全性研究[J]. 中国药学(英文版), 2021, 30(3): 206-217.
[3]	周艳, 宋恒文, 邵志超, 尹博民, 付西美, 谢典佑, 韦利军. 一种新的细胞周期蛋白依赖性激酶(CDK)9抑制剂QHRD107对急性髓系白血病的临床前疗效[J]. 中国药学(英文版), 2021, 30(2): 146-156.
[4]	杨秀伟, 张友波, 徐嵬. 静脉和灌胃给予大鼠茴香酸对羟基苯乙酯的RP-HPLC法测定和药代动力学研究[J]. 中国药学(英文版), 2020, 29(11): 804-812.
[5]	杨辉, 胡小鹏, 杨晓勇, 刘航, 任亮, 王玮, 刘丽宏, 张小东. 肾移植术后糖皮质激素和他克莫司的药代动力学相互作用[J]. 中国药学(英文版), 2019, 28(4): 257-263.
[6]	刘鑫, 张波, 梅丹, 黄凯. HPLC-MS/MS法测定大鼠血浆中异绿原酸B浓度及其在药代动力学研究中的应用[J]. 中国药学(英文版), 2019, 28(3): 167-173.
[7]	张玲玲, 张慧文, 武世奎, 刘宏, 李静媛, 董馨, 夏慧敏, 王焕芸. UPLC-Q-Exactive-MS 同时测定三臣丸中六种活性成分的药代动力学研究[J]. 中国药学(英文版), 2019, 28(11): 812-824.
[8]	欧阳文鹃, 张亚兰, 徐平声, 戴智勇, 马虹英, 秦群. 国产注射用甲磺酸帕珠沙星在健康人体的药代动力学研究[J]. 中国药学(英文版), 2019, 28(1): 40-48.
[9]	常馨予, 郭桂明, 范峥, 王宏蕾, 刘洋, 韩丽娟. UPLC-MS/MS法测定黄芪桂枝五物汤在大鼠血浆中两种活性成分及药代动力学研究[J]. 中国药学(英文版), 2018, 27(4): 263-272.
[10]	姜华, 杨景明, 曹玲, 贾桂枝, 戴红良, 孟祥才. 高温胁迫对防风药材药代动力学和药效的影响[J]. 中国药学(英文版), 2018, 27(2): 109-115.
[11]	代华灵, 高伟祺, 张国顺, 王锐利, 张淑秋. 青蒿素脂质纳米粒的制备及药动学评价[J]. 中国药学(英文版), 2017, 26(3): 180-186.
[12]	崔婷, 周岐新, 张丹, 蒋心惠. 五种大黄蒽醌类化合物在家兔和大鼠体内的分布和药代动力学[J]. 中国药学(英文版), 2017, 26(2): 115-123.
[13]	朱刚直, 易勤, 范志宏, 马岳慧, 王丹丹, 王磊, 程泽能. LC-MS/MS法测定大鼠血浆中PAC-1的新型抗癌衍生物的浓度及其药物动力学研究[J]. 中国药学(英文版), 2017, 26(11): 811-818.
[14]	文周, 冀闪, 谢非凡, 胡高云, 程泽能. 高效液相色谱法测定大鼠血浆中新型抗纤维化药物美氟尼酮的浓度及其药物动力学研究[J]. 中国药学(英文版), 2017, 26(1): 45-52.
[15]	谢湘, 周瑞, 周培根, 余鹏, 高峰. LC-MS-MS法测定人血浆中的替诺福韦[J]. 中国药学(英文版), 2016, 25(9): 676-682.